Big Sale! 10 stocks to give 20-60% returns post April-June earnings

Sat, Aug 03, 2013 at 17:16

| Source:
Share   .   Email   .   Print      

Jubilant Life Sciences

Target Price Rs 129

Implied Upside 53.6%


Rationale: While the sign of rising prices in PPES would help Jubilant to boost LSI business, we are concerned on pricing pressure in its major Pharma products. The company maintains average sales growth of 20-21%, with EBITDA margin at 21% in near-to-medium term. Jubilant’s core EPS 4.7 is in line with expectation, though we believe that high competition in Pharma products would increase margin risk.

Explore Moneycontrol

Copyright © Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of is prohibited.